论文部分内容阅读
肝炎相关性肝脏疾病是引起应用抗逆转录联合治疗HIV感染者发病与死亡的主要病因之一。为了评估HBV和(或)HCV联合感染中国HIV感染者预后的影响。来自中国疾病预防控制中心的Zhang F等根据2010-2012年来自中国国家免费抗逆转录病毒治疗项目的数据进行了一项全国范围的回顾性队列研究。对项目中超过18周岁并开始进行标准化抗逆转录病毒治疗的HBV和HCV阳性的患者随访至2012年12月31日。研究使用Kaplan-Meier分析和Cox比例
Hepatitis-associated liver disease is one of the major causes of the onset and death of HIV-infected patients with antiretroviral therapy. To assess the impact of HBV and / or HCV co-infection on the prognosis of HIV-infected individuals in China. Zhang F et al from the Chinese Center for Disease Control and Prevention conducted a nationwide retrospective cohort study based on data from the national free antiretroviral treatment program in China for 2010-2012. Patients with HBV and HCV who were over 18 years of age and started standardized antiretroviral therapy in the project were followed up until December 31, 2012. The study used Kaplan-Meier analysis and Cox scale